Afinum Invests in Formulation Development Specialist ProJect Pharmaceutics

Deutsch: Orrick berät Afinum bei Investment in ProJect Pharmaceutics

Afinum invests in ProJect Pharmaceutics GmbH, a leading formulation development specialist for biologics and complex small molecules with a particular focus on antibody-drug conjugates (ADCs).

Orrick represented Afinum.

THE COMPANIES

Since its founding in 2000, Afinum has been one of the leading private equity firms for medium-sized companies in the German-speaking region. With offices in Munich, Frankfurt and Zurich, Afinum combines deep market knowledge in the DACH region with an international investor perspective and specializes in succession and growth investments within four technology-driven verticals.

ProJect Pharmaceutics was founded in 2010 and is headquartered in Planegg, near Munich. Through its proven track record of solving critical challenges in drug development with its technology-enabled approach, ProJect Pharmaceutics has built trusted, long-term relationships with its customer base of blue-chip global biopharma companies and innovative biotechnology companies.

THE IMPACT

This acquisition represents the eleventh and final platform investment for the Afinum 9 fund. The investment further underlines Afinum's commitment to backing outstanding founder-led businesses in the healthcare sector.

Together with its two founders, Andreas Schütz and Klaus Hellerbrand, who will remain significant co-investors, Afinum will support ProJect Pharmaceutics in accelerating its growth trajectory.

THE TEAM

Christoph Brenner led the Orrick team which further included Stefan Riedl, Maria Teodorescu, André Zimmermann, Marianna Urban, Benedikt Migdal and Lars Mesenbrink.